Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.64 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | CCR8 | P51685 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745644 | 1.00 | HDAC8 (0.64) | HDAC8ACHEBCHEOPRM1HDAC1 | |
| SCHEMBL28631404 | 0.87 | HDAC8 (0.70) | HDAC8ACHEBCHEHDAC1HDAC6 | |
| SCHEMBL7496089 | 0.83 | HDAC8 (0.75) | HDAC8HDAC1HDAC6SIGMAR1 | |
| SCHEMBL7496085 | 0.83 | HDAC8 (0.75) | HDAC8HDAC1HDAC6SIGMAR1 | |
| SCHEMBL3602069 | 0.82 | SMN1; SMN2 (0.58) | — | |
| SCHEMBL3602065 | 0.82 | SMN1; SMN2 (0.58) | — | |
| SCHEMBL8541810 | 0.81 | L3MBTL1 (0.62) | HDAC8HDAC1HDAC6ALDH1A1 | |
| SCHEMBL8541807 | 0.81 | L3MBTL1 (0.62) | HDAC8HDAC1HDAC6ALDH1A1 | |
| SCHEMBL13600028 | 0.80 | ALDH1A1 (0.56) | OPRM1ALDH1A1CCR8KDM4EABL1 | |
| SCHEMBL17128024 | 0.79 | L3MBTL1 (0.45) | ALDH1A1SIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | HDAC8 3113/4885ACHE 2066/4885BCHE 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.